**Клеточная терапия болезни Паркинсона: достижения и перспективы**



**Авторы: Юркевич М.Ю.(1), Зафранская М.М.(1), Пономарев В.В.(1), Бойко А.В.(1), Алейникова Н.Е.(2)**(1) — ГУО «Белорусская медицинская академия последипломного образования», г. Минск, Республика Беларусь
(2) — УЗ «5-я городская клиническая больница», г. Минск, Республика Беларусь
Резюме

Обзор литературы посвящен основным направлениям, проблемам и перспективам использования клеточной терапии при болезни Паркинсона. В течение последних десятилетий проведены многочисленные экспериментальные и клинические исследования, основанные на использовании в терапии паркинсонизма дофамин-секретирующих клеток (клетки мозгового слоя надпочечников и сонного гломуса), клеток фетального мезенцефалона, генетически модифицированных клеток, а также стволовых клеток различного происхождения, в том числе эмбриональных, мезенхимальных, нейрональных и индуцированных плюрипотентных стволовых клеток. Несмотря на значительный прогресс в данной области, для практического внедрения представленных подходов необходимо решить ряд вопросов, связанных с этическими и техническими факторами, достаточно высокой вариабельностью исходов клеточной терапии, наличием в ряде случаев побочных эффектов, риском онкотрансформации, необходимостью стандартизации протоколов направленной нейрогенной дифференцировки.

This review focuses on the main trends, opportunities and challenges of cell therapy application in Parkinson’s disease. During the past decades, countless experimental and clinical studies were held based on introducing various means of treatment parkinsonism, such as dopamine-producing cells, fetal brain tissue cells, genetically modified cells, as well as stem cells of different origin, including embryonic, neural, mesenchymal and induced pluripotent stem cells. While considerable progress has been made in this area, several practical aspects still require further consideration, including those involving ethical and technical factors, significant variability of the outcomes, side effects and oncological risks, as well as the need for induced neural differentiation protocol unification and compatibility.

Список литературы

1. Lihachev S.A. Parkinson’s disease: the modern possibility of therapy / S.A. Lihachev, V.V. Vojtov, V.V. Vashhilin // Neurology and neurosurgery in Belarus. — 2009. — № 2. — P. 23-38.

2. Tropnikova G.K. Neuroinflammation и Parkinson’s disease / G.K. Tropnikova // News of biomedical science. — 2011. — V. 4, № 4. — P. 204-2015.

3. Neuroendocrine abnormalities in Parkinson’s disease / E. De Pablo-Fernandez, D.P. Breen, P.M. Bouloux et al. // J. Neurol. Neurosurg. Psychiatry. — 2017. — V. 88, № 2. — P. 176-185.

4. Connolly B.S. Pharamacological treatment of Parkinson disease: a review / B.S. Connolly, A.E. Lang // JAMA. — 2014. — V. 311, № 16. — Р. 1670-1683.

5. Krack P. Current application and limitions of surgical treatments for movement disorders / P. Krack, R. Martinez-Fernandez, M. Del Alamo, J.A. Obeso // Mov. Disord. — 2017. — V. 32, № 1. — P. 36-52.

6. Lunn J.S. Stem Cell Technology for Neurodegenerative Diseases / J.S. Lunn, S.A. Sakowski, J. Hur, E.L. Feldman // Ann. Neurol. — 2011. — V. 70, № 3. — P. 353-361.

7. Transplantation of adrenal medullary tissue to striatum in parkinsonism. First clinical trials / E.O. Backlund, P.O. Granberg, B. Hamberger et al. // J. Neurosurg. — 1985. — V. 62, № 2. — Р. 169-173.

8. Open microsurgical autograft of adrenal medulla to the right caudate nucleus in two patients with intractable Parkinson’s disease / I. Madrazo, R. Drucker-Colin, V. Diaz et al. // N. Engl. J. Med. — 1987. — V. 316, № 14. — P. 831-834.

9. Unsicker K. The trophic cocktail made by adrenal chromaffin cells / K. Unsicker // Exp. Neurol. — 1993. — V. 123, № 2. — P. 167-173.

10. Transplant of cultured neuron-like differentiated chromaffin cells in a Parkinson’s disease patient. A preliminary report / R. Drucker-Colin, L. Verdugo-Díaz, C. Morgado-Valle et al. // Arch. Med. Res. — 1999. — V. 30, № 1. — P. 33-39.

11. Anaya-Martinez V. Effects of graft placement site on the survival of adrenal medulla transplantant into the brain and its relation with the recovery of motor function // V. Anaya-Martinez, E. Montiel-Flores, J. Espinosa-Villanueva, F. Garcia-Hernandez // Arch. Med. Res. — 2000. — V. 31, № 6. — P. 551-557.

12. Anisimov S.V. Cell therapy of Parkinson`s disease: embryonic and adult tissue transplantation / S.V. Аnisimov // Progress of gerontology. — 2008. — V. 21, № 4. — P. 575-592.

13. Kompoliti K. Neuropathological study 16 years after autologous adrenal medullary transplantation in a Parkinson’s disease patient / K. Kompoliti, Y. Chu, K.M. Shannon, J.H. Kordower // Mov. Disord. — 2007. — V. 22, № 11. — P. 1630-1633.

14. Watts R.L. Intrastriatal cografts of autologous adrenal medulla and sural nerve in MPTP-induced parkinsonian macaques: behavioral and anatomical assessment / R.L. Watts, A.S. Mandir, R.A. Bakay // Cell Transplant. — 1995. – V. 4, № 1. — P. 27-38.

15. Date I. Chromaffin cell survival and host dopaminergic fiber recovery in a patient with Parkinson`s disease treared by cograft of adrenal medulla and pretransected peripheral nerve. Case report //

I. Date, T. Imaoka, Y. Miyoshi, T. Ono, S. Asari, T. Ohmoto // J. Neurosurg. — 1996. — V. 84, № 4. — P. 685-689.

16. Bresjanac M. Xenogeneic adrenal medulla graft rejection rather than survival leads to increased rat striatal tyrosine hydroxylase immunoreactivity / M. Bresjanac, J., Sagen, G. Seigel, C.L. Paino, K.J. Kordower, D.M. Gash // Neuropathol. Exp. Neurol. — 1997. — V. 56, № 5. — P. 490-498.

17. Hansen J.T. Paraneuronal grafts in unilateral 6-hydroxydopamine-lesioned rats: morphological aspects of adrenal chromaffin and carotid body glomus cell implants / J.T. Hansen, G.Y. Вing, M.F. Notter, D.M. Gash // Prog. Brain Res. — 1988. — V. 78. — P. 507-511.

18. Espejo E.F. Cellular and functional recovery of Parkinsonian rats after intrastriatal transplantation of carotid body cell aggregates / E.F. Espejo, R.J. Montoro, J.A. Armengol, J. Lopez-Barneo // Neuron. — 1998. — V. 20, № 2. – P. 197-206.

19. Porzionato A. Trophic factors in the carotid body / A. Porzionato, V. Macchi, A. Parenti, R. De Caro // Int. Rev. Cell. Mol. Biol. — 2008. — V. 269. — P. 1-58.

20. Carotid body autotransplantation in Parkinson disease: a clini–cal and positron emission tomography study / A. Mínguez-Castellanos, F. Escamilla-Sevilla, G.R. Hotton et al. // J. Neurol. Neurosurg. Psychiatry. — 2007. — V. 78, № 8. — P. 825-831.

21. Grafts of fetal dopamine neurons survive and improve motor function in Parkinson’s disease / O. Lindvall, P. Brundin, H. Widner et al. // Science. — 1990. — V. 247. — P. 574-577.

22. Transplantation of embryonic dopamine neurons for severe Parkinson’s disease / Freed C.R., Greene P.E., Breeze R.E. et al. // N. Engl. J. Med. — 2001. — V. 344. — P. 710-719.

23. Kordower J.H. Lewy body — like pathology in long-term embryonic nigral transplants in Parkinson’s disease / J.H. Kordower,

Y. Chu, R.A. Hauser, T.B. Freeman, C.W. Olanow // Nature Medicine. — 2008. — V. 14. — P. 504-506.

24. Mendez I. Dopamine neurons implanted into people with Parkinson’s disease survive without pathology for 14 years / I. Mendez,

A. Vinuela, A. Astradsson // Nature Medicine. — 2008. — V. 14. — P. 507-509.

25. Extensive graft-derived dopaminergic innervation is maintained 24 years after transplantation in the degenerating parkinsonian brain / Li W., Englund E., Widner H. et al. // Proc. Natl. Acad. Sci. U.S.A. — 2016. — V. 113, № 23. — P. 6544-6549.

26. Politis M. Graft-induced dyskinesia in Parkinson`s disease: high striatal serotonin/dopamine transporter ratio / M. Politis, W.H. Oertel, K. Wu et al. // Mov. Dis. — 2011. — V. 26, № 11. — P. 1997-2003.

27. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson`s disease / C.W. Olanow, C.G. Goetz, J.H. Kordower et al. // Ann. Neurol. — 2003. — V. 54, № 3. — P. 403-414.

28. Zhusupova A.S. Fetal neurotransplantation in Parkinson`s disease: the fist results / А.S. Zhusupova // Clinical gerontology. — 2006. — № 11. — P. 74-76.

29. Braam S.R. Feeder-free culture of human embryonic stem cells in conditioned medium for efficient genetic modification / S.R. Braam, C. Denning, E. Matsa, L.E. Young, R. Passier, C.L. Mummery // Nat. Protoc. — 2008. — V. 3, № 9. — P. 1435-1443.

30. Kim H.J. Regionally specifield human neural progenitor cells derived from the mesencephalon and forebrain undergo increased neurogenesis following overexpression of ASCL1 / H.J. Kim, E. McMillan, F. Han, C.N. Svendsen // Stem Cells. — 2009. — V. 27, № 2. — P. 390-398.

31. Han F. Development of stem cell-based therapy for Parkinson’s disease / F. Han, D. Baremberg, J. Gao, J. Duan, X. Lu, N. Zhang, Q. Chen // Tramslational Neurogeneration. — 2015. — V. 4. — P. 1-16.

32. Buttery P.C. Treating Parkinson`s disease in the 21st century: can stem cell transplantation complete? / P.C. Buttery, R.A. Barker // J. Comp. Neurol. — 2014. — V. 21, № 3. — P. 2802-2816.

33. Büchele F. Two-step grafting significantly enhances the survival of fetal dopaminergic transplants and induces graft-derived vascularisation in a 6-OHDA model of Parkinson’s disease / F. Büchele, M. Döbrössy, C. Hackl, A. Papazoglou, G. Nikkhah // Neurobiol. Dis. — 2014. — V. 68. — P. 112-125.

34. Clarkson E.D. Strands of embryonic mesencephalic tissue show greater dopamine neuron survival and better behavioral improvement than cell suspensions after transplantation in parkinsonian rats / E.D. Clarkson, W.M. Adams, K.P. Bell, C.R. Freed // Brain Res. — 1998. — V. 806, № 1. — Р. 60-68.

35. Anisimov S.V. Cell therapy of Parkinson’s disease:the use of neonatal, fetal and embryonic stem cells / S.V. Аnisimov // Progress of gerontology. — 2009. — V. 22, № 2. — P. 296-315.

36. Epigenetic activation of the Foxa2 gene is required for maintaining the potential of neural precursorcells to differentiate into dopaminergic neurons after expansion / S.Y. Bang, S.H. Kwon, S.H. Yi et al. // Stem Cells Dev. — 2015. — V. 24, № 4. — P. 520-533.

37. Lee S.H. Efficient generation of midbrain and hindbrain neurons from mouse embryonic stem cells / S.H. Lee, N. Lumelsky, L. Studer, J.M. Auerbach, R.D. McKay // Nature Biotechnology. — 2000. — V. 18. — P. 675-679.

38. Nakamura M. Differentiation patterns of mouse embryonic stem cells and induced pluripotent stem cells into neurons / M. Nakamura, Y. Kamishibahara, A. Kitazawa, H. Kawaguchi, N. Shimizu // Cytotechnology. — 2016. — V. 68, № 3. — P. 409-417.

39. Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson’s disease / S. Kriks, J.-W. Shim, J. Piao et al. // Nature. — 2011. — V. 480. — P. 547-551.

40. Transplantation of human embryonic stem cell-derived cells to a rat model of Parkinson’s disease: effect of in vitro differentiation on graft survival and teratoma formation / A. Brederlau, A.S. Correia, S.V. Anisimov et al. // Stem Cells. — 2006. — V. 24, № 6. — P. 1433-1440.

41. Failure of bone marrow cells to transdifferentiate into neural cells in vivo / R.F. Castro, K.A. Jackson, M.A. Goodell et al. // Science. — 2002. — V. 297. — P. 1299.

42. Chen D. Therapeutic effects of intranigral transplantation of mesenchymal stem cells in rat models of Parkinson’s disease / D. Chen, W. Eu, W. Zhuang, C. Lv, F. Li, X. Wang // J. Neurosci. Res. — 2017. — V. 95, № 3. — P. 907-917.

43. Anisimov S.V. Cell therapy of Parkinson’s disease: the use of somatic stem cells / S.V. Аnisimov // Progress of gerontology. — 2009. — V. 22, № 1. — P. 150-166.

44. Robinson A.P. Human stem/progenitor cells from bone marrow enhance glial differentiation of rat neural stem cells: a role for transforming growth factor β and Notch signaling / A.P. Robinson, J.E. Foraker, J. Ylostalo, D.J. Prockop // Stem Cells Dev. — 2011. — V. 20, № 2. — Р. 289-300.

45. Munoz J.R. Human stem/progenitor cells from bone marrow promote neurogenesis of endogenous neural stem cells in the hippocampus of mice / J.R. Munoz, B.R. Stoutenger, A.P. Robinson, J.L. Spees, D.J. Prockop // Proc. Natl. Acad. Sci. U.S.A. — 2005. — V. 102. — P. 18171-18176.

46. Mesenchymal stem cells inhibit transmission of α-synuclein by modulating clathrin-mediated endocytosis in a parkinsonian model / S.H. Oh, H.M. Kim, H.J. Park et al. // Cell Reports. — 2016. — V. 14. — P. 835-849.

47. Mesenchymal stem cells and immunomodulation: current status and future prospects / F. Gao, S.M. Chiu, D.A. Motan et al. // Cell Death and Disease. — 2016. — V. 7. — P. 1-11

48. Transplantation of bone marrow mesenchymal stem cells decreases oxidative stress, apoptosis, and hippocampal damage in brain of a spontaneous stroke model / M.L. Calio, D.S. Marinho, G.M. Ko, R.R. Ribeiro et al. // Free Radic. Biol. Med. — 2014. — V. 70. — P. 141-154.

49. Mu M.W. Comparative studies of neural differentiation of bone marrow mesenchymal stem cells by different induction methods // M.W. Mu, Z.Y. Zhao, C.G. Li // Gen. Mol. Res. — 2015. — V. 14, № 4. — P. 14165-14176.

50. The generating of neuroblasts from bone marrow stroma and their clinical use in nervous system diseases / V.A. Javorskaya, N.P. Voloshina, V.V. Hvisyuk et al. // Ukrainian neurosurgical journal. — 2006. — № 4. — P. 89-95.

51. Kitada M. Parkinson’s disease and mesenchymal stem cells: potential for cell-based therapy / M. Kitada, M. Dezawa, J. Li et al. // Parkinson’s Disease. — 2012. doi: 10.1155/2012/873706.

52. Intravenous administration of mesenchymal stem cells exerts therapeutic effects on parkinsonian model of rats: focusing on neuroprotective effects of stromal cell-derived factor-1α / F. Wang, T. Yasuhara, T. Shingo et al. // Neuroscience. — 2010. — V. 11. — P. 52.

53. Open-labeled study of unilateral autologous bone-marrow-derived mesenchymal stem cell transplantation in Parkinson’s disease / N.K. Venkataramana, S.K. Kumar, S. Balaraju et al. // Transl. Res. — 2010. — V. 155, № 2. — Р. 62-70.

54. Mitochondrial dysfunction of immortalized human adipose tissue-derived mesenchymal stromal cells from patients with Parkinson’s disease / H.E. Moon, S.H. Yoon, Y.S. Hur et al. // Exp. Neurobiol. — 2013. — V. 22, № 4. — P. 283-300.

55. Rapid single-step induction of functional neurons from human pluripotent stem cells / Y. Zhang, C.H. Pak, Y. Han et al. // Neuron. — 2013. — V. 17, № 5. — P. 785-798.

56. Wernig M., Zhao J.P., Pruszak J. et al. Neurons derived from reprogrammed fibroblasts functionally integrate into the fetal brain and improve symptoms of rats with Parkinson’s di–sease // Proc. nat. Acad. Sci. USA. — 2008. — Vol. 105, № 15. — P. 5856-5861.

57. Islamov R.R. Genetic and cell therapy of neurodegenerative diseases / R.R. Islamov, A.A. Rizvanov, D.S. Guseva, A.P. Kijasov // Gene and cells. — 2007. — V. 2, № 3. — P. 29-39.

58. Therapeutic benefit of TH-engineered mesenchymal stem cells for Parkinson’s disease / L. Lu, C. Zhao, Y. Liu et al. // Brain Res. Protoc. — 2005. — V. 15. — P. 46-51.

59. Wyse R.D. Use of genetically modified mesenchymal stem cells tо treat neurodegeneration diseases // R.D. Wyse, C.L. Dunbar, J. Rossignol // Int. J. Mol. Sci. — 2014. — V. 15. — P. 1719-1745.